Viral Hemorrhagic Fever
Symptoms, Doctors, Treatments, Advances & More

Viral Hemorrhagic Fever Overview

Save information for later
Sign Up

Learn About Viral Hemorrhagic Fever

What is the definition of Viral Hemorrhagic Fever?
Viral hemorrhagic fevers is a term used to describe a group of illnesses caused by four different families of viruses that severely affect multiple body systems. Some of the more commonly known types of viral hemorrhagic fevers include Ebola virus, Lassa fever, Hantavirus, Tick-borne encephalitis, and Rift Valley fever. Viral hemorrhagic fevers are carried by insects, rats, and mice and are limited to specific geographical areas in which the insects and animals live, such as West Africa (Lassa fever). While humans can be infected by contact with an infected insect or animal, these viruses can also be transmitted from one human to another and are highly contagious.
What are the symptoms of Viral Hemorrhagic Fever?
While certain types of viral hemorrhagic fevers may cause only mild illness, many of these can cause severe, life-threatening symptoms, and even death. Symptoms may also include muscle aches, extreme fatigue, and high fever. An infected person’s vascular system is often damaged, while the body loses ability to regulate. Vascular damage causes hemorrhage (bleeding).
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Viral Hemorrhagic Fever?
Most viral hemorrhagic diseases have no treatment. However, the antiviral drug, ribavirin, may help to shorten the course of illness, and, in some cases, may even prevent infection. Patients are mainly treated with supportive care, which includes prevention of dehydration. Some patients may need kidney dialysis in the event of kidney failure.
Who are the top Viral Hemorrhagic Fever Local Doctors?
Elite in Viral Hemorrhagic Fever
Dr. Anna P. Durbin
Infectious Disease
Elite in Viral Hemorrhagic Fever
Dr. Anna P. Durbin
Infectious Disease

The Johns Hopkins Hospital

1800 Orleans Street, 
Baltimore, MD 
410-955-5000
Languages Spoken:
English
See accepted insurances

Dr. Anna Durbin is an associate professor at the Johns Hopkins University School of Medicine. Her area of clinical expertise is infectious disease. Dr. Durbin earned her M.D. from Wayne State University School of Medicine. She completed her residency and performed a fellowship in infectious diseases at Detroit Medical Center. She has expertise in the evaluation of live attenuated flavivirus vaccines, primary dengue and West Nile virus vaccines, and the early evaluation of malaria vaccines. She has served on national and international advisory boards and committees related to dengue and malaria vaccine safety. An important research interest of hers is studying the immunopathogenesis of dengue infection and disease. In addition to her clinical studies, her laboratory is also developing an animal model of dengue using rhesus macaques. Dr. Durbin is rated as an Elite provider by MediFind in the treatment of Viral Hemorrhagic Fever. Her top areas of expertise are Dengue Fever, Viral Hemorrhagic Fever, Arbovirosis, and Yellow Fever.

Elite in Viral Hemorrhagic Fever
Dr. Eric S. Halsey
Infectious Disease
Elite in Viral Hemorrhagic Fever
Dr. Eric S. Halsey
Infectious Disease

Emory University Hospital Midtown Campus

550 Peachtree Street Northeast, MedicalOfficeTower, 
Atlanta, GA 
404-686-8114
Experience:
27+ years
Languages Spoken:
English
See accepted insurances

Eric Halsey is an Infectious Disease provider in Atlanta, Georgia. Dr. Halsey has been practicing medicine for over 27 years and is rated as an Elite provider by MediFind in the treatment of Viral Hemorrhagic Fever. His top areas of expertise are Dengue Fever, Viral Hemorrhagic Fever, Malaria, and Togaviridae Disease.

 
 
 
 
Learn about our expert tiers
Learn More
David C. Lye
Elite in Viral Hemorrhagic Fever
David C. Lye
Elite in Viral Hemorrhagic Fever
David C. Lye
12 Science Drive 2, 
Singapore, SG 

David Lye practices in Singapore, Singapore. Mr. Lye is rated as an Elite expert by MediFind in the treatment of Viral Hemorrhagic Fever. His top areas of expertise are Dengue Fever, Viral Hemorrhagic Fever, Methicillin-Resistant Staphylococcus Aureus (MRSA), COVID-19, and Hepato-Pancreato-Biliary Surgery.

View All Doctors
What are the latest Viral Hemorrhagic Fever Clinical Trials?
A Phase 3, Randomized, Double-Blind, Placebo-Controlled (Older Adults, Aged >60 to 79 Years) and Open-Label (Adults, Aged 45 to 60 Years), Multicenter Trial to Investigate the Safety and Immunogenicity of a Dengue Tetravalent Vaccine (TDV) Administered Subcutaneously to Adults and Older Adults With or Without Comorbidities in Endemic Areas for Dengue
A Phase 3, Randomized, Double-Blind, Placebo-Controlled (Older Adults, Aged >60 to 79 Years) and Open-Label (Adults, Aged 45 to 60 Years), Multicenter Trial to Investigate the Safety and Immunogenicity of a Dengue Tetravalent Vaccine (TDV) Administered Subcutaneously to Adults and Older Adults With or Without Comorbidities in Endemic Areas for Dengue
Enrollment Status: Recruiting
Publish Date: February 09, 2026
Intervention Type: Biological, Other
Study Phase: Phase 3

Summary: Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever. Researchers have seen that dengue fever now also happens more often in elderly persons. The main aim of this study is to learn more about the side effects of TDV in adult (45 - 60 years) and elderly (60 - 79 years) persons and about TDV's ability to create ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Efficacy, Tolerability and Safety of New or Repurposed Drugs Against Lassa Fever in West African Countries
Efficacy, Tolerability and Safety of New or Repurposed Drugs Against Lassa Fever in West African Countries
Enrollment Status: Recruiting
Publish Date: February 04, 2026
Intervention Type: Drug
Study Phase: Phase 2/Phase 3

Summary: Lassa fever (LF) is a viral haemorrhagic fever responsible of 5000 deaths per year in West Africa, with in-hospital mortality at 12%. Transmission to humans occurs mainly via direct or indirect exposure to excreta from the rodent reservoir, mainly made up of Mastomys natalensis . Less frequently, LASV may also be transmitted from human to human and cause nosocomial outbreaks. Ribavirin is the only...

View All Clinical Trials